Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coacillium - Legacy Healthcare

Drug Profile

Coacillium - Legacy Healthcare

Alternative Names: Coacillium cutaneous solution - Legacy Healthcare; Coacillium oral solution - Legacy Healthcare; Coacillium topical solution - Legacy Healthcare; Coacillium®; LH-8; LH8 - Legacy Healthcare; Topical Coacillium 21%

Latest Information Update: 12 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Legacy Healthcare
  • Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies
  • Mechanism of Action E selectin expression inhibitors; Intercellular adhesion molecule-1 expression inhibitors; Interleukin-8 expression inhibitors; Ki-67 antigen expression stimulants; Proto oncogene protein c bcl 2 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Alopecia areata
  • Clinical Phase Unknown Alopecia
  • Preclinical Fatigue
  • Research Atopic dermatitis; Psoriasis

Most Recent Events

  • 12 Mar 2024 Clinical trials in Alopecia (Topical) prior to March 2024 (Legacy Healthcare pipeline, March 2024)
  • 12 Mar 2024 Early research in Atopic dermatitis in Switzerland (Topical) prior to March 2024 (Legacy Healthcare pipeline, March 2024)
  • 12 Mar 2024 Early research in Psoriasis in Switzerland (Topical) prior to March 2024 (Legacy Healthcare pipeline, March 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top